SMTL ID : 8pwc.1 (2 other biounits)

Crystal structure of MDM2 with Brigimadlin

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.46 Å

Oligo State

monomer

Ligands

1 x G7I: Brigimadlin

G7I.1: 18 residues within 4Å: Chain A: S.2, L.39, F.40, L.42, G.43, I.46, M.47, Y.52, H.58, L.67, F.71, F.76, V.78, K.79, H.81, I.84, Y.85, I.88 15 PLIP interactions: 15 interactions with chain A Hydrophobic interactions: A:L.39, A:L.39, A:L.42, A:I.46, A:Y.52, A:F.76, A:V.78, A:K.79, A:I.84 Hydrogen bonds: A:L.39, A:H.81 Water bridges: A:S.2 Salt bridges: A:H.58 pi-Stacking: A:H.81 Halogen bonds: A:H.81

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Gollner, A. et al., Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Mol.Cancer Ther. (2024)

Release Date

2024-10-02

Peptides

E3 ubiquitin-protein ligase Mdm2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

E3 ubiquitin-protein ligase Mdm2

Related Entries With Identical Sequence